Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06893939 · ClinicalTrials.gov registry record · Phase 3
Limited Versus Extended Trophic Feeding (LET-FEED) Trial
A Phase 3 study of Sepsis and Mortality, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
- 6
- Study locations
NCT06893939: Recruiting Phase 3 study of Sepsis and Mortality, sponsored by University of Washington.
NCT06893939 is a Phase 3 study of Sepsis and Mortality that is actively recruiting participants, run by University of Washington. The registered enrollment target is 350 participants, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06893939, a Phase 3 study of Sepsis and Mortality, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
- 6
- Study locations
Study Summary
Study Hypothesis/Question In infants born very preterm, advancing enteral feeds after 24 hours from birth (limited trophic feeds) versus after 72 hours (extended trophic feeds) reduces the risk of all-cause late onset sepsis (LOS) without increasing the risk of other adverse outcomes. Study Design Type This is a multi-center, open-label, parallel-group, individual randomized controlled trial comparing two different trophic feeding regimens in preterm infants born between 25w0d and 31w6d. These infants will be randomly assigned to either the intervention group, receiving limited trophic feeding (20 to 25 mL/kg/day for one day) or the control group, receiving extended trophic feeding (20 to 25 mL/kg/day for three days) prior to advancing enteral feeds until full feeding volume (140 mL/kg/day) is achieved. Eligibility Criteria Preterm infants with gestational ages between 25 0/7 and 31 6/7 weeks and a birthweight of \<1500 grams who are admitted to six participating neonatal units will be eligible for inclusion. Infants with \<5th percentile for weight at birth, vasopressor use within first 24 hours of life major congenital/genetic anomalies affecting enteral feeding, growth, or mortality, and those with a terminal illness in which decisions to withhold or limit support have been made will be excluded. Infants of parents or legal guardians who are unable to provide consent within 36 hours of birth will also be excluded. Study Intervention/Methods Written parental informed consent will be obtained prenatally or within the first 36 hours of birth. Infants will be randomized to receive limited trophic feeds of 24 to 36 hours or extended trophic feeds for 72 hours prior to the advancement of enteral feeds. Infants will be fed parent's own milk (POM) with donor human milk as the alternative if POM is unavailable. Primary Outcome Late-onset sepsis, defined as positive blood, urine, and/or cerebrospinal fluid (CSF) cultures in the presence of compatible clinical signs of
Primary Outcome
Defining LOS: For the purposes of this study, a positive finding of LOS will be defined as the following: a body fluid culture (e.g. blood, urine, CSF) that returns positive, obtained in the presence of compatible clinical signs of sepsis (e.g. hypotension, apnea/bradycardia, increasing oxygen requirements, increasing metabolic acidosis, lactic acidosis, hypoglycemia, hyperglycemia, etc.) occurring after 72 hours from birth and before hospital discharge that was treated with antibiotics for a mi
Conditions Studied
Interventions
- OTHER Limited Trophic Feeds (1 day of trophic feeds)
- OTHER Extended Trophic Feeds (3 days of trophics)
Study Locations (6)
Washington
- University of Washington - Seattle
- St. Joseph's Medical Center - Tacoma
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- University of South Florida - Tampa
Oklahoma
- University of Oklahoma - Oklahoma City
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2025-07-03 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 3 |
What NCT06893939 shows while recruiting
NCT06893939 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Limited Trophic Feeds (1 day of trophic feeds) is the first listed.
NCT06893939 lists 6 locations in 5 states (Washington, Alabama, Florida).
Frequently Asked Questions
What is clinical trial NCT06893939 about?
NCT06893939 is a clinical study titled "Limited Versus Extended Trophic Feeding (LET-FEED) Trial". Study Hypothesis/Question In infants born very preterm, advancing enteral feeds after 24 hours from birth (limited trophic feeds) versus after 72 hours (extended trophic feeds) reduces the risk of all-cause late onset sepsis (LOS) without increasing the risk of other adverse outcomes. Study Design ...
What is the current status of trial NCT06893939?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2025-07-03. Estimated completion is 2028-03-31.
What conditions does trial NCT06893939 study?
This clinical trial studies the following conditions: Sepsis, Mortality, Length of Stay.
What interventions are being tested in trial NCT06893939?
The interventions under investigation include: Limited Trophic Feeds (1 day of trophic feeds) (OTHER), Extended Trophic Feeds (3 days of trophics) (OTHER).
Who is sponsoring clinical trial NCT06893939?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06893939 being conducted?
This trial has 6 study locations across Alabama, Florida, Oklahoma, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06893939's enrollment target sits among peer trials
350 30th of 90 higher than 60 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
RECRUITING · Phase 3
-
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
COMPLETED · Phase 3
-
The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
COMPLETED · Phase 3
-
Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants
COMPLETED · Phase 3
-
Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion
COMPLETED · Phase 3
-
The APS Phenotyping Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI